跳到正文
原文
Medical Xpress·· 10 天前精选AI 评分65

前列腺癌联合用药增加毒性但无明显额外临床益处

Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations

AI 导读

一项多中心随机II期ZZ-FIRST临床试验评估了恩杂鲁胺联合奥拉帕利与恩杂鲁胺单药治疗高肿瘤负荷转移性激素敏感前列腺癌的效果。结果显示,联合用药在无可靶向突变的肿瘤中未见明显额外临床益处,但增加了毒性。

推荐理由

研究显示联合用药在无可靶向突变的肿瘤中未见明显额外临床益处,但增加了毒性,提示需谨慎选择治疗方案。

正文 · 原文
Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations
Spatial transcriptomic data overview and tumor transcriptomic adaptation to AR inhibition. Credit: Nature Medicine (2026). DOI: 10.1038/s41591-026-04671-5

The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enzalutamide alone in patients with high-tumor-burden metastatic prostate cancer who had not previously received hormone therapy.

This work, the results of which were published in Nature Medicine, also included the study of tumor adaptation that leads to resistance to hormonal therapy, known as castration resistance.

With an estimated 1.5 million new cases and 397,000 deaths worldwide in the year 2022, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men, with worldwide cases projected to double by 2040.

Although most cases are diagnosed when the disease is localized, metastases are detected in up to 10% of patients—these cases account for more than half of prostate cancer deaths. Patients with metastatic disease initially respond to treatment with ARPI, but tumors frequently develop resistance leading to disease recurrence.

The ZZ-FIRST academic clinical trial included 54 patients with high-volume metastatic hormone-naïve prostate cancer (mHNPC) who were randomized 1:2 to receive the investigational enzalutamide-talazoparib combination (37 patients) or enzalutamide alone (17 patients).

Median radiographic progression-free survival (rPFS) was 45.3 months with talazoparib plus enzalutamide versus 31.1 months with enzalutamide monotherapy. The findings also showed that the time to PSA progression—a blood-based prostate cancer biomarker—and the development of castration resistance was longer in patients treated with the investigational combination.

"Overall, talazoparib plus enzalutamide showed clinical activity in patients with high-tumor-burden metastatic hormone-sensitive prostate cancer, but the combination did not demonstrate a clear additional clinical benefit over enzalutamide monotherapy in patients whose tumors did not have actionable mutations, and was associated with increased toxicity," observed Francesca Zacchi, clinical investigator of VHIO's Prostate Cancer Group and first author of the study.

One key strength of this study is the integration of longitudinal tumor biopsies with spatially resolved transcriptomic analyses within the framework of a randomized clinical trial. Using this approach, the investigators tracked how the disease changed and adapted over time and space to systemic treatment directly in patients, and without the need to solely rely on preclinical models or cross-sectional clinical datasets. Furthermore, biological analyses performed on these biopsies before and during treatment enabled the research team to study how tumors adapted to androgen receptor pathway inhibition.

Results showed profound reprogramming of gene activity, with a decrease in cell division and proliferation. However, this reduction did not translate into a functional loss of DNA repair capacity. "DNA repair genes are expressed at lower levels primarily because tumor cells proliferate less, as opposed to having acquired an actual deficiency in this pathway," said Joaquin Mateo, medical oncologist at the Vall d'Hebron University Hospital, head of VHIO's Prostate Cancer Group and corresponding author of the study.

From tumor genomics to clinical trials: A decade of evidence building

The story of PARPi in prostate cancer began with a simple, yet at the time unanswered question: Can we identify patients who are most likely to benefit from a specific treatment before administering it?

In 2015, an initial trial led by Mateo demonstrated that the PARPi olaparib was effective in patients with metastatic castration-resistant prostate cancer with alterations in DNA repair genes, including BRCA1, BRCA2 and ATM. For the first time, the investigators reported a causal link between a molecular biomarker and a drug response in prostate cancer—an approach known as precision medicine. This work opened a line of research that subsequently yielded robust results, ultimately leading to the approval of this class of drugs in this setting.

Two key questions remained unanswered: Could this benefit be extended to patients without these mutations, and could it be generated artificially by blocking the androgen receptor pathway? Investigations using laboratory models suggested that hormone treatment could impair the DNA repair capacity of tumor cells, which, in theory, would make them more vulnerable to PARPi, irrespective of genetic profile.

To test this hypothesis directly in patient tumors, Mateo's group designed the ZZ-FIRST trial. Unlike previous trials, ZZ-FIRST included a period of hormone treatment prior to randomization, which allowed for the collection of tumor biopsies both before and during androgen blockade, enabling the researchers to analyze—with spatial resolution—how tumors adapt to treatment. In a sense, it was the experimental answer to the biological question that had guided a decade of research.

Implications for future therapy

The results of the ZZ-FIRST trial align with emerging data from another, larger phase 3 study, which show that the benefit of combinations of ARPI and PARPi is clearly greater in patients whose tumors harbor alterations in DNA repair genes such as BRCA1, BRCA2, CDK12, PALB2 or ATM.

He concluded: "Our results therefore reinforce the importance of implementing biomarker testing to determine which patients may derive benefit from these strategies, especially in the earlier stages of disease when it is crucial to carefully weigh the balance between clinical benefit and long-term toxicity."

Publication details

Francesca Zacchi et al., Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04671-5

Journal information: Nature Medicine

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations (2026, November 10) retrieved 10 November 2026 from https://medicalxpress.com/news/2026-11-prostate-cancer-drug-combination-toxicity.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com